These findings suggest that hAMSCs secretome promotes cell death and induces S phase cell cycle arrest in MDA-MB-231 cells, suggesting its potential as a novel approach in cancer therapy.

18 hours ago

Preclinical • Journal

MDM2 (E3 ubiquitin protein ligase) • CHEK2 (Checkpoint kinase 2) • CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)

TP53 mutation • ATM mutation

Uterine inflammatory myofibroblastic tumor: a clinicopathological and molecular genetic analysis of eight cases (PubMed, Zhonghua Bing Li Xue Za Zhi)

The patient was treated with the oral targeted drug crizotinib and died of multiple organ failure 18 months after surgery...UIMT and EIMS that exhibit aggressive behavior typically possess a greater number of genetic alterations. The abnormal expression of p53 or p16 protein, when combined with clinicopathological parameters, can serve as indicators for predicting the adverse biological behavior of tumors.

4 days ago

Journal

ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • ANK2 (Ankyrin 2)

TP53 mutation • ALK positive • ATM mutation • ALK rearrangement • ALK fusion

Xalkori (crizotinib)

14d

A Presentation of Meckel's Diverticulum With Malignancy. (PubMed, Cureus)

Undifferentiated carcinoma should be considered in the differential diagnosis of large mesenteric masses. This case emphasizes the importance of recognizing atypical presentations of MD and the critical role of molecular characterization in guiding personalized therapy when conventional management strategies are limited.

14 days ago

Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase)

TMB-H • MSI-H/dMMR • ATM mutation

14d

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening (clinicaltrials.gov)

P=N/A, N=79, Recruiting, Memorial Sloan Kettering Cancer Center

14 days ago

New trial

TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • APC (APC Regulator Of WNT Signaling Pathway) • EPCAM (Epithelial cell adhesion molecule) • PRSS1 (Serine Protease 1) • CTRC (Chymotrypsin C)

TP53 mutation • BRCA1 mutation • ATM mutation • STK11 mutation • PALB2 mutation

24d

Comparing Genetic Testing Completion among Breast Cancer Patients When Ordered by a Surgeon Versus a Genetic Specialist. (PubMed, Kans J Med)

Offering genetic testing directly within the breast surgeon's clinic was associated with significantly higher completion rates compared with referral-based testing. Integrating genetic testing into surgical consultations may reduce logistical barriers and enable earlier use of genetic information in treatment planning.

24 days ago

Journal • BRCA Biomarker

BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2)

ATM mutation • CHEK2 mutation

27d

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations (clinicaltrials.gov)

P2, N=32, Active, not recruiting, Academic and Community Cancer Research United | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Aug 2026

27 days ago

Enrollment closed • Trial completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • ATR (Ataxia telangiectasia and Rad3-related protein) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)

BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation

Lynparza (olaparib)

29d

Liquid Biopsy in Advanced Prostate Cancer. (PubMed, Cancers (Basel))

Emerging approaches, including fragmentomics and methylation profiling, offer improved tumor specificity and may help overcome these limitations. Together, these advances support the integration of liquid biopsy into clinical practice for personalized management and longitudinal monitoring in prostate cancer.

29 days ago

Review • Journal • Liquid biopsy • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

ATM mutation

29d

Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions. (PubMed, NPJ Breast Cancer)

Moreover, 208 potential neo-peptide targets (median per patient n = 3) were detected across recurrently mutated genes such as ATM, CREBBP, IRS2, KEAP1, MSH6, NOTCH1, NOTCH2, POLD1, TP53, and TSC2. Molecular profiling of residual disease in extensively poor responding TNBC post-NAC revealed multiple potentially targetable variant, supporting the use of next-generation sequencing to guide personalized strategies for these high-risk TNBC patients.

29 days ago

Journal • BRCA Biomarker

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • RB1 (RB Transcriptional Corepressor 1) • NOTCH1 (Notch 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • MSH6 (MutS homolog 6) • TSC2 (TSC complex subunit 2) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • POLD1 (DNA Polymerase Delta 1) • IRS2 (Insulin receptor substrate 2)

TP53 mutation • ATM mutation

30d

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov)

P1, N=44, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed

30 days ago

Trial completion

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)

BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • CHEK1 mutation

Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)

30d

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (clinicaltrials.gov)

P2, N=51, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: May 2026 --> May 2027

30 days ago

Trial completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha)

BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation

Lynparza (olaparib)

A Rare Case of Cutaneous Lymphomatoid Granulomatosis: A Case Report and Literature Review. (PubMed, Cureus)

The ulcer improved without any further intervention. This case underscores the need for heightened clinical suspicion, repeat tissue sampling, and early dermatologic evaluation, which are critical for diagnosis.

1 month ago

Journal

ATM (ATM serine/threonine kinase) • CD4 (CD4 Molecule)

ATM mutation